Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab alone or with tremelimumab versus standard of care in first-line recurrent or metastatic squamous cell head and neck cancer
2015-003589-10Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Oct 2015
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in head and neck squamous cell carcinoma (HNSCC) comparing Durvalumab monotherapy, Durvalumab + tremelimumab and Standard of care (3 arms). Primary endpoint: Overall survival in the PD-L1 TC/IC subgroup. Started Oct 2015; status: completed.
02
Drugs
durvalumabtremelimumab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on 2015-003589-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-003589-10.